|
|  |
|
|  Acura
Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in
research, development and manufacture of innovative Aversion® (abuse deterrent)
Technology and related product candidates.
Aversion®
Technology
 Aversion®
Technology is a
patented platform for developing pharmaceutical products containing
potentially abuseable drugs including oxycodone, hydrocodone, oxymorphone,
hydromorphone, morphine, codeine, tramadol, propoxyphene, and many other
opioid analgesics. 
We believe this platform technology
is also applicable to non-opioid
products that are subject to abuse and which fall into two broad categories,
central nervous system ("CNS") depressants (including tranquilizers and
sedatives) and stimulants.
Aversion® Technology is applicable to orally administered
tablets and capsules. In addition to the active ingredient, Aversion® Technology
utilizes certain proprietary combinations of functional inactive ingredients and active
ingredients intended to discourage the most common methods of pharmaceutical
product misuse and abuse including;
(i) intravenous injection of dissolved tablets or
capsules,
(ii) nasal snorting of crushed tablets or capsules
(iii) intentional swallowing of excessive quantities of tablets or
capsules
. . .
More
Acurox™ Tablets
Acurox™
Tablets (oxycodone HCl and niacin),
is the Company’s lead product candidate with Aversion® (abuse deterrent)
Technology. . .
More
Commercial Agreements
In December 2007, Acura and King Pharmaceuticals Research
and Development, Inc. (“King”), a wholly-owned subsidiary of King
Pharmaceuticals, Inc., closed a License, Development and
Commercialization Agreement (the “King Agreement” or "Agreement") to
develop and commercialize in the United States, Canada and Mexico (the
"King Territory") certain opioid analgesic products utilizing our
proprietary Aversion® Technology including Acurox™ Tablets. The
Agreement provides King with an exclusive license in the King Territory
for Acurox™ Tablets and another undisclosed opioid product candidate
utilizing Aversion® Technology. In addition, the King Agreement
provides King with an option to license in the King Territory all future
opioid analgesic products developed utilizing Acura's Aversion®
Technology. We encourage you to
review the Company’s filings with Securities and Exchange Commission for
more details about the King Agreement. . .
More
Patents and Trademarks
In April 2007, the United States Patent and Trademark Office (the “USPTO”)
issued to the Company U.S. Patent No. 7,201,920 titled ”Methods and
Compositions for Deterring Abuse of Opioid Containing Dosage Forms” and in
June 2008, the USPTO issued to the Company a Notice of Allowance for a
non-provisional patent application titled “Methods and Compositions for
Deterring Abuse of Opioid Containing Dosage Forms”
. . .
More |
| |
|
|
|
|
